Synthetic analog of Lovastatin. Potent competitive HMG-CoA reductase inhibitor. Anti-hypercholesterolemic agent. Cholesterol/isoprenoid biosynthesis inhibitor. Blocks the production of mevalonate, a critical compound in the production of cholesterol and isoprenoids. Inhibits the isoprenylation of Ras and Rho family GTPases. Smooth muscle cell proliferation inhibitor. Anti-adhesive, immunomodulatory and anti-inflammatory compound. Proteasome modulator. Stimulates bone formation. Apoptosis inducer. Anticancer compound. Increases cellular resistance to anticancer agents such as doxorubicin and etoposides. Suppresses ICAM-1-LFA-1 interactions, which blocks virus replication and infection. Anti-hypertensive agent. Suppresses TNF-induced NF-kappaB activation.
Storage and Stability:
Short-term Storage: +4°C
Long-term Storage: -20°C
Stable for at least 2 years after receipt when stored at -20°C.
Purity: >98% (HPLC)
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference: |
Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia: M.J. Mol, et al.; Lancet 2, 936 (1986)
All ras proteins are polyisoprenylated but only some are palmitoylated: J.F. Hancock, et al.; Cell 57, 1167 (1989)
Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types: P. Negre-Aminou, et al.; Biochim. Biophys. Acta 1345, 259 (1997)
Statins as a newly recognized type of immunomodulator: B. Kwak, et al.; Nat. Med. 6, 1399 (2000)
Lovastatin and simvastatin are modulators of the proteasome: C. Wojcik, et al.; Int. J. Biochem. Cell Biol. 32, 957 (2000)
Statins and bone formation: I.R. Garrett, et al.; Curr. Pharm. Des. 7, 715 (2001)
HMG-CoA reductase inhibitors as immunomodulators: potential use in transplant rejection: L.J. Raggatt & N.C. Partridge; Drugs 62, 2185 (2002) (Review)
HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis: W.W. Wong, et al.; Leukemia 16, 508 (2002)
The statins as anticancer agents: K.K. Chan, et al.; Clin. Cancer Res. 9,10 (2003)
Anti-inflammatory and immunomodulatory effects of statins: L.M. Blanco-Colio, et al.; Kidney Int. 63, 12 (2003)
Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1: J.F. Giguere & M.J. Tremblay; J. Virol. 78, 12062 (2004)
HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma: J.I. Cohen; Br. J. Canc. 92, 1593 (2005)
Beyond lipid lowering: the anti-hypertensive role of statins: V. Chopra, et al.; Cardiovasc. Drugs Ther. 21, 161 (2007)
Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway: K.S. Ahn, et al.; Biochem. Pharmacol. 75, 907 (2008)
|Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.|